Bangavax, also known as Bancovid, is a COVID-19 vaccine candidate developed by a Bangladeshi pharmaceutical company Globe Biotech Limited. The vaccine was initially called Bancovid. On 23 November 2021, Globe Biotech has received ethical authorization from the Bangladesh Medical Research Council to conduct the first human trial. __TOC__ ==History== On 2 July 2020, Globe Biotech Limited announced to be the first company from Bangladesh to have a COVID-19 vaccine under development. The lone Bangladeshi company actually developed three COVID-19 vaccine candidates with different technologies. The company named the mRNA based vaccine as Bancovid then renamed to Bangavax. Globe Biotech took all the necessary steps from December 2020 to January 2021 to get the permission for ethical approval to conduct the first clinical trial of Bangavax. The Bangladesh government has been criticized for not approval the vaccine even after months to conduct the first clinical trial without any explanation.
Globe Biotech published full research data in the Vaccine journal in May 2021.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).